P
PrognomiQ
Transforms healthcare and early disease detection through the power of multi-omics data
About PrognomiQ
PrognomiQ is a cutting-edge health technology startup that operates in the field of proteomics, genomics, and metabolomics. The company's primary focus is on early disease detection, leveraging the latest advances in these fields to generate a comprehensive understanding of a person's biological state, including the state of disease.
Read full description
PrognomiQ's business model revolves around generating proprietary proteomic data at an unprecedented scale and depth. This data is then supplemented with genomic, metabolomic, and other health data to create a holistic view of a person's health. The company's unique approach allows them to discover innovative methods for early disease detection, which are then translated into transformative test products.
The company's clients are primarily in the healthcare sector, including hospitals, clinics, and other medical institutions. By providing these entities with advanced tools for early disease detection, PrognomiQ aims to revolutionize the way diseases are diagnosed and treated.
The company generates revenue by selling these transformative test products to its clients. Additionally, the company's proprietary multi-omics platform, which is designed to generate proteomic, genomic, and metabolomic data at scale, serves as a powerful engine for the development of future healthcare products.
In conclusion, PrognomiQ is a promising startup that is poised to make significant contributions to the field of early disease detection. By leveraging the power of proteomics, genomics, and metabolomics, the company is well-positioned to develop innovative solutions that could potentially impact millions of lives.
At a glance
- Status
- Operational
- Founded
- 2020
- Headquarters
- San Mateo, United States
- Employees
- 46
- Open positions
- None listed
- Dealroom signal
- 66.2/100
- Industry
- Health
- Sub-industry
- Health Platform
- Sector
- Health Tech & Medtech, Oncology, Hard Tech, proteomics, DT and LS, science-based
- Technology
- Deep Tech
- Business model
- SaaS
- Client focus
- b2b
Latest news
Press, funding announcements and product moves mentioning PrognomiQ.
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| LATE VCOther financing | Aug 2025 | $10M | $230M | Undisclosed | ↗ |
| SERIES DOther financing | Nov 2024 | $34M | $230M | Catalio Capital Management · Seer · Invus · Bruker | ↗ |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
Growth signals
Latest recorded traffic for PrognomiQ is 4.4K monthly website visits, up 51.7% over the last three months. PrognomiQ's team declined 20.7% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A10 investors entered at this stage
aMoon Fund
Wing Venture Capital
Invus
Bruker
Emerson Collective- FMFidelity Capital Management
Maverick Ventures
Catalio Capital Management
Wing
T. Rowe Price
Series B and later1 investor entered at this stage
Seer
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about PrognomiQ on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See PrognomiQ’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.